Close Button Icon
Doptelet (avatrombopag) Tablets Logo

You are about to leave doptelethcp.com and go to an external page.

Please note that Sobi is not responsible for the content of the website you are about to visit.

CONTINUE

Go back

This information is intended for healthcare professionals in the United States.

Are you a healthcare professional?

Yes

No
Close Button Icon

Discover the Copay Assistance Program

Eligible commercially insured patients may qualify for the Doptelet Copay Assistance Program

What's the program?

  • Eligible patients may pay as little as $0 for each Doptelet prescription
  • Annual maximum benefit up to $15,000

Eligible patients must:

  • Have commercial insurance that covers Doptelet
  • Not be enrolled in any state or covered by a state or federal healthcare program such as Medicare, Medicaid, Medigap, Veterans Affairs (VA), Department of Defense (DOD), or TRICARE
  • Be 18 years of age or older
  • Be a resident in the United States or a US Territory
  • Be prescribed Doptelet for an FDA-approved use

How to enroll:

  • Approved pharmacies, healthcare professionals, and Doptelet Connect can enroll patients
  • Patients can enroll themselves as well as their caregivers
  • Please call 1-833-368-2663 Monday–Friday 8 am–8 pm ET for more information

Terms and Conditions

  • Patients pay as little as $0 per prescription. Copay Assistance Program has an annual calendar cap of $15,000
  • Patient has an on-label prescription
  • The Copay Assistance Program is void where prohibited by law, taxes, or restricted
  • This offer is non-transferable, no substitutions are permissible, and this offer cannot be combined with any other rebate/coupon, free trial, or similar offer for the specified prescription
  • Sobi, Inc. reserves the right to rescind, revoke, or amend this offer at any time without notice
  • The Copay Assistance Program for Doptelet is not insurance and is not intended to substitute for insurance
  • Patients, pharmacists, and healthcare providers must not seek reimbursement from health insurance or any third party for any part of the benefit received by the patient through this Copay Assistance Program. Patients must not seek reimbursement from any health savings, flexible spending, or other healthcare reimbursement accounts for the amount of assistance received from the Copay Assistance Program
  • Certain information pertaining to your use of the Copay Assistance Program will be shared with Sobi, Inc., the sponsor of the Copay Assistance Program. The information disclosed will include the date the prescription is filled, the number of pills or product dispensed by the pharmacists, and the amount of your copay that will be paid for by using this Copay Assistance Program. For more information, please see the Sobi Privacy Policy at https://sobi-northamerica.com/privacy-policy
  • Acceptance in this Copay Assistance Program is not conditioned on any past, present, or future purchase, including additional doses
  • Enrollment for the Copay Assistance Program is valid through the calendar year
  • Sobi reserves the right to change Copay Assistance Program terms at any time
Close Button Icon
  • For US healthcare professionals only

  • About Doptelet
  • Efficacy
  • Safety
  • Dosing
  • Access
  • Resources
    • ITP Resources
    • Video Library
    • FAQs
  • Request a Rep
  • For US healthcare professionals only

  • Important Safety Information
  • Prescribing Information
  • Patient Information Leaflet
  • For Patients
Doptelet (avatrombopag) Tablets Logo

For US healthcare professionals only

  • About Doptelet
  • Efficacy
  • Safety
  • Dosing
  • Access
  • Resources
    • ITP Resources
    • Video Library
    • FAQs
  • Request a Rep

DOPTELET IS THE FASTEST-GROWING TPO-RA1**

Based on year-over-year financial market growth data for TPO-RAs from fiscal year 2021 compared to fiscal year 2022.1

Reference: 1. Data on file. TPO-RA Market Growth. 2023: Sobi, Inc.

Request a Rep

DOPTELET NOW HAS PARITY ACCESS WITH ELTROMBOPAG AT SOME OF THE LARGEST COMMERCIAL PLANS1

Use our look-up tool to see if your commercial plan is eligible for Doptelet.

Reference: 1. Data on file. CAM Conversion Guide. 2022: Sobi, Inc.

Learn more about
Doptelet access here

RAISE & MAINTAIN
Platelet counts

Doptelet® (avatrombopag) is a fast-acting, long-lasting TPO-RA for chronic ITP.1,2*

Rapid and durable response1†

Patients on Doptelet reached target platelet counts of 50,000/μL for a median of 12.4 cumulative weeks.1

Rapid Onset Graph

In as few as 8 days, 66% of Doptelet patients reached 50,000 platelets per microliter.1

Core Study: Efficacy was evaluated in a 6-month, multicenter, randomized, double-blind, placebo-controlled Phase 3 study. Patients had previously received one or more prior chronic ITP therapies and had average screening and baseline platelet counts of <30×109/L. Forty-nine patients were randomized (2:1) to receive either Doptelet (n=32) or placebo (n=17).

  • The primary efficacy endpoint was the cumulative number of weeks of platelet response, defined as a platelet count ≥50×109/L in the absence of rescue therapy, over 6 months of once-daily treatment in adults with chronic ITP. Doptelet-treated patients had a median duration of 12.4 cumulative weeks vs 0 weeks for placebo
  • A secondary efficacy endpoint was the proportion of patients with a platelet response (platelet counts ≥50×109/L) at Day 8. 66% (n=21/32) of Doptelet-treated patients had platelet counts of ≥50,000/μL at Day 8 compared to placebo (n=0/17)

Open-label extension: Patients could enter the open-label extension phase if they completed the 6-month core study, or if they experienced a lack of efficacy during that period. In the extension phase, all patients received titrated Doptelet once daily. Thirty-nine patients (24 Doptelet and 15 placebo) entered the 90-week maintenance period of the extension phase, in which Doptelet dose titration and downward titration of concomitant ITP medications were allowed. At the end of the extension phase, a 4-week, dose-tapering period was followed by a 30-day follow-up after the last dose of Doptelet.2,4

  • The primary endpoint of the extension study was to assess the long-term safety and efficacy of treatment with Doptelet by measuring platelet response rate, bleeding, and the use of rescue therapy2
  • Exploratory endpoints included the percentage of patients who achieved platelet counts ≥50,000/μL or ≥100,000/μL at any time during the core study and its extension phase. These endpoints were reported in an integrated analysis of the Phase 3 core study and extension phase data. In an integrated analysis of the core study and its extension phase, 93.8% of patients initially randomized to Doptelet and who continued to be treated with Doptelet during the extension phase achieved a platelet count of ≥50,000/μL at any time, compared to 64.7% of placebo patients who rolled over to Doptelet.4,6

With Doptelet, nearly every patient can reach their treatment goal3,4

  • Patients treated with Doptelet in clinical trials had a mean baseline platelet count of 14.1x109/L, and mean platelet count of 62.7x109/L at Week 26
  • 94% of patients reached 50,000 platelets/μL at least once during the pivotal trial or open-label extension
    • The study was not placebo-controlled; therefore, causality cannot be attributed, and hypothesis testing cannot determine whether within-arm changes were due to drug effect. The Extension Study may not meet the FDA definition of an adequate and well-controlled study due to its study design.
  • 38% of patients reached a complete response by Day 8 of 100,000 platelets/μL (N=32)
  • Platelet counts remained above baseline for more than a year with Doptelet2

Throughout the core study and extension phase, 72.3% of patients were exposed to avatrombopag for at least 32 weeks. In the open-label extension phase for those patients continuing Doptelet treatment, a response was achieved at 44.2% of visits.2,6

ASH guidelines define a durable response as platelet count ≥30x109/L and at least doubling of the baseline count at 6 months.

Target platelet count window in pivotal trial was ≥50x109/L to ≤150x109/L.

Dop•Tell•Us The Data

Doptelet Clinical Trials Results
Visit the video library to view more.

View Video
Dop•Tell•Us The Data
Visit the video library to view more presentations.
View Video

References:

  1. 1. DOPTELET [package insert]. Durham, NC: AkaRx, Inc.
  2. 2. Jurczak W, Chojnowski K, Mayer J, et al. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018;183(3):479-490.
  3. 3. Data on file. 2014: Sobi, Inc.
  4. 4. Nagalla S, Vredenburg M, Tian W, Allen LF. Platelet response to avatrombopag in patients with chronic immune thrombocytopenia: additional analyses from a phase 3 study and its extension. Blood. 2019;134(suppl 1):1071.
  5. 5. Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019;3(23):3829-3866.
  6. 6. Al-Samkari H, Aggarwal K, Vredenburg M, Tian W, Allen LF. Long-term response rates in patients with chronic immune thrombocytopenia treated with avatrombopag: additional analyses from a phase 3 study and its extension phase. Blood. 2019;134(suppl1):2356.
INDICATION & IMPORTANT SAFETY INFORMATION

INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Thrombotic/Thromboembolic Complications. DOPTELET is a thrombopoietin (TPO) receptor agonist and TPO receptor agonists have been associated with thrombotic complications in patients with chronic liver disease (0.4%; (1/274) in DOPTELET-treated patients) and thromboembolic complications in patients with chronic immune thrombocytopenia (7%; (9/128) in DOPTELET-treated patients). Portal vein thrombosis has been reported in patients with chronic liver disease, and thromboembolic events (arterial and venous) have been reported in patients with chronic immune thrombocytopenia treated with TPO receptor agonists.

Consider the potential increased thrombotic risk when administering DOPTELET to patients with known risk factors for thromboembolism, including genetic prothrombotic conditions.

DOPTELET should not be administered to patients with chronic liver disease or chronic immune thrombocytopenia in an attempt to normalize platelet counts. Monitor platelet counts, and for signs and symptoms of thromboembolic events and institute treatment promptly.

Serious Adverse Reactions

Serious adverse reaction that occurred more frequently in patients treated with DOPTELET (9%; 12/128) compared to placebo (5%; 1/22) was headache, occurring in 1.6% (2/128).

Adverse Reactions

The most common adverse reactions (≥10%) in patients with chronic immune thrombocytopenia were headache, fatigue, contusion, epistaxis, upper respiratory tract infection, arthralgia, gingival bleeding, petechiae, and nasopharyngitis.

Postmarketing Experience

Following the approval of DOPTELET, hypersensitivity reactions involving the immune system, including, but not limited to, pruritus, rash, choking sensation, swollen face, and swollen tongue have been reported.

These are not all the possible risks associated with DOPTELET. Please see Full Prescribing Information for DOPTELET at www.doptelethcp.com

To report suspected adverse reactions, contact Sobi North America at 1-866-773-5274 or FDA at 1-800-FDA-1088.

For WAC pricing, visit doptelethcp.com/wac-pricing.

Sobi Rare Strength Logo
Terms of Use
Privacy Policy
Contact Us
Unsubscribe
White YouTube Logo

Doptelet is a registered trademark of AkaRx, Inc., a Sobi company.
Sobi is a trademark of Swedish Orphan Biovitrum AB (publ)
Doptelet Connect is a trademark of AkaRx, Inc.
© 2023 Sobi, Inc. – All rights reserved.

PP-14799v2   03/23

INDICATION & IMPORTANT
SAFETY INFORMATION
Open ISI Button
Close ISI Button

INDICATION

DOPTELET® (avatrombopag) is indicated for the treatment of thrombocytopenia in adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

Scroll To Top Button

This website uses cookies. By continuing to use this website, you consent to our use of these cookies.

Read more about our use of cookies